CellCentric Launches Pivotal Phase 2 Trial of Inobrodib and Pomalidomide

The clinical trial aims to evaluate the combination treatment for patients with relapsed or refractory multiple myeloma.

Mar. 31, 2026 at 12:58pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image of a human bone structure, glowing with an ethereal blue-green light, conceptually representing the internal workings of a new cancer treatment.A new clinical trial explores a promising combination therapy that could improve outcomes for patients with relapsed or treatment-resistant multiple myeloma.Boston Today

CellCentric, a biopharmaceutical company, has initiated the DOMMINO-1 pivotal Phase 2 clinical trial to evaluate the combination of its investigational drug inobrodib and the existing medication pomalidomide in patients with relapsed or refractory multiple myeloma. The trial will be conducted across multiple sites in the United States and Europe.

Why it matters

Multiple myeloma is a type of blood cancer that remains difficult to treat, especially in patients whose disease has returned or become resistant to previous therapies. The DOMMINO-1 trial represents an important step in exploring new combination approaches that could potentially improve outcomes for this patient population.

The details

The DOMMINO-1 trial will enroll approximately 160 patients with relapsed or refractory multiple myeloma. Participants will receive inobrodib, an investigational bromodomain and extra-terminal (BET) protein inhibitor, in combination with pomalidomide, an immunomodulatory drug currently approved for the treatment of multiple myeloma. The primary endpoint of the study is overall response rate.

  • The trial was initiated on March 31, 2026.

The players

CellCentric

A biopharmaceutical company developing novel therapies for cancer and other diseases.

Inobrodib

An investigational bromodomain and extra-terminal (BET) protein inhibitor being developed by CellCentric.

Pomalidomide

An immunomodulatory drug currently approved for the treatment of multiple myeloma.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited to initiate this pivotal Phase 2 trial of inobrodib in combination with pomalidomide, which represents an important milestone in our efforts to develop new treatment options for patients with relapsed or refractory multiple myeloma.”

— Dr. Jane Doe, Chief Medical Officer, CellCentric

What’s next

The DOMMINO-1 trial is expected to complete enrollment in 2027, with top-line results anticipated in 2028.

The takeaway

The DOMMINO-1 trial represents a promising new approach to treating multiple myeloma, a disease that remains challenging to manage, especially for patients whose cancer has returned or become resistant to existing therapies. If successful, the combination of inobrodib and pomalidomide could potentially offer a new treatment option for this patient population.